What the FDA labels say about taking them together
Elbasvir/grazoprevir and rifampin
Elbasvir/grazoprevir's FDA label of March 13, 2026 names rifampin in its contraindications section; the rifampin label PlainMeds reads does not name elbasvir/grazoprevir.
Check it at the source: the elbasvir/grazoprevir FDA label on DailyMed (effective March 13, 2026, Merck Sharp & Dohme LLC); the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.).
What does the elbasvir/grazoprevir label say about rifampin?
Elbasvir/grazoprevir label, contraindicationsNamed in a table that the FDA label file prints without its column breaks; the full label shows the table.
Source: FDA drug label (ZEPATIER), Merck Sharp & Dohme LLC, effective March 13, 2026 (SPL set 164dc02a-9180-426a-b8b5-04ab39d2bbd4), via openFDA; the full label on DailyMed
What does the rifampin label say about elbasvir/grazoprevir?
Rifampin's label (effective February 11, 2026) does not name elbasvir/grazoprevir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Elbasvir/grazoprevir | Rifampin | |
|---|---|---|
| Labeled for | Hepatitis C | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $0.679 per capsule 300 mg capsule |
| Shortage now | A presentation being discontinued | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once